What is the effectiveness of different statins for children with familial hypercholesterolemia?
Summary of the Evidence

Risks
No statistically significant differences were found between statins and placebo regarding increase in aspartate aminotransferase levels (AST) (4 RCT, 4 events RR 2.40, 95%CI 0.29,19.85) or in alanine aminotransferase levels (ALT) (4 RCT, 3 events, RR 2.03, 95%CI 0.24,16.95) at 6 months. There were no differences in global incidence of adverse events (3 RCT, 162 events, RR 1.02, 95%CI 0.85,1.27) at 6 months.
Applicability
Statins are an effective intervention for the reduction of cholesterol levels in children with FH. However, close pediatric follow-up is warranted because of possible hepatotoxicity or myotoxicity. In addition the dosage used across studies varied greatly and duration of follow-up was relatively short (average 1 year).
If the disease is mild, treatment can be delayed until the age of 18.
Commentaries There is moderate to high level of evidence showing that treatment with statins in children can improve biochemical outcomes such as levels of LDL, HDL and total cholesterol in blood in comparison to placebo. In addition overall incidence of adverse events seems to be similar. More uncertainty exists in the effects of statins on triglyceride levels or liver function.
There is no information on critical outcomes such as the incidence of vascular events or atherosclerosis progression.
Costs
No studies on cost-effectiveness have been identified in the current literature. 
